Nesterov V V, Beliaev D L, Kuznestov V P
Antibiot Khimioter. 1993 Jan;38(1):62-8.
Leukinferon was used in adoptive immunotherapy of sepsis in risk group newborns by activation of the donor leukocyte suspension in combination with etiotropic, antitoxic and other agents of chemotherapy. It accelerated the recovery at the average of 7 days in comparison with the control (the routine treatment). The favourable time course of the major immunological indices such as leukocytosis and absolute and relative counts of lymphocytes mainly due to correction of the T-lymphocyte count, NBT and LII impaired by the pathological process was recorded at the average 4 days earlier against the control. By the end of the treatment normalization of the above mentioned indices proved to be more complete. Neither complications of the septic process nor side effects of the immunotherapy were observed.
通过激活供体白细胞悬液并联合病因治疗、抗毒素及其他化疗药物，白细胞干扰素被用于高危组新生儿败血症的过继免疫治疗。与对照组（常规治疗）相比，其平均在7天内加速了恢复。主要免疫指标如白细胞增多以及淋巴细胞的绝对和相对计数的有利时间进程，主要是由于T淋巴细胞计数、NBT和LII因病理过程受损而得到纠正，平均比对照组提前4天记录到。到治疗结束时，上述指标的正常化更为完全。未观察到败血症过程的并发症或免疫治疗的副作用。
